Pfizer Corporation

Morphic Therapeutic, Inc.

Pharmacia & Upjohn Company

Bruce Nelsen Rogers

Lei Zhang

Michael Aaron Brodney

Steven Victor O'Neil

Scot Richard Mente

Jennifer Elizabeth Davoren

Ivan Viktorovich Efremov

Aleksey I Gerasyuto

Matthew Gregory Bursavich

Blaise S Lippa

David Lawrence Firman Gray

Bryce Alden Harrison

Dawn M Troast

Fu-Yang Lin

Amy Beth Dounay

Kyle D Konze

Kristopher N Hahn

Mats A Svensson

Michael Eric Green

Chewah Lee

Alexey Alexandrovich Lugovskoy

Jaclyn Louise Henderson

Eric Jon Jacobsen

Christopher Ryan Butler

Elizabeth Mary Beck

Cheng Zhong

Byungchan Kim

Tyler Day

David W Piotrowski

Vincent E Groppi, Jr

Brian Sosa

Brian Thomas O'Neill

Chakrapani Subramanyam

Erik Alphie LaChapelle

Jason K Myers

James E Dowling

Gabriela Barreiro

Alice L Bodnar

Eugene R Hickey

Patrick Robert Verhoest

Justin Ian Montgomery

Brad A Acker

Jeffrey W Corbett

Mark Brewer

Adam Matthew Gilbert

Christopher John Helal

Laura Ann McAllister

Douglas Scott Johnson

Damien Webb

Andrea Bortolato

Qi Qiao

Robert Zahler

Jackson B Hester, Jr

Kristine E Frank

Michael D Ennis

Daniel Patrick Walker

Donn G Wishka

Salma Rafi

Dan Cui

Susan L Vander Velde

Evelyne Houang

Gregory Wayne Kauffman

Kapildev Kashmirilal Arora

Natasha Mariam Kablaoui

Danica Antonia Rankic

Matthew Francis Dunn

Erik Alphie Lachapelle

Steven Victor O'neil

David Lawrence Gray

Brian Thomas O'neill

Angrea Bortolato

David L F Gray

Steven V O'NEIL

Disclosed are small molecule inhibitors of αvβ6 integrin, and methods of using them to treat a number of diseases and conditions.

Inhibiting (α-v)(β-6) integrin

Inhibitors of (αv)(β6) integrin

Disclosed are small molecule antagonists of α4β7 integrin, and methods of using them to treat a number of specific diseases or conditions.

Antagonists of human integrin α4β7

Disclosed are small molecule inhibitors of αvβ6 integrin, and methods of using them to treat a number of specific diseases or conditions.

Inhibitors of (α-v)(β-6) integrin

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCI, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, Tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction, migraine, SLE, hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.

Heteroaromatic compounds and their use as dopamine D1 ligands

Disclosed are small molecule inhibitors of &#x3b1;v&#x3b2;6 integrin, and methods of using them to treat a number of diseases and conditions.

Inhibitors of (&#x3b1;-v)(&#x3b2;-6) integrin

Disclosed are small molecule inhibitors of &#x3b1;v&#x3b2;6 integrin, and methods of using them to treat a number of specific diseases or conditions.

Inhibiting (&#x3b1;-v)(&#x3b2;-6) integrin

Disclosed are small molecule antagonists of human &#x3b1;&#x3b2;integrin, and methods of using them to treat a number of diseases and conditions.

Inhibiting human integrin (alpha-4) (beta-7)

Disclosed are small molecule antagonists of &#x3b1;4&#x3b2;7 integrin, and methods of using them to treat a number of specific diseases or conditions.

Antagonists of human integrin (&#x3b1;4)(&#x3b2;7)

Inhibiting human integrin (&#x3b1;-4) (&#x3b2;-7)

Inhibitors of (alpha-v)(beta-6) integrin

Inhibiting (&#x3b1;-V)(&#x3b2;-6) integrin

Growing community of inventors

Belmont, MA, United States of America

Bruce Nelsen Rogers